The pharmaceutical patent landscape in Europe has shifted in ways that most of the industry’s public commentary has missed. The […]

The 505(b)(2) pathway is the pharmaceutical industry’s most capital-efficient regulatory route, and it is widely misunderstood. Ask ten drug developers

The $50 Million Problem Nobody Wants to Talk About Most pharmaceutical executives treat patent litigation as a legal department problem.

The pharmaceutical industry’s patent defense system is a machine built on a single assumption: that the price of a drug

An investigative deep-dive for commercial leads, market access directors, and C-suite executives who negotiate with OptumRx, Express Scripts, and CVS

Every week, a medicinal chemistry team somewhere identifies a promising compound, runs it past the IP group, and asks a

Every procurement director who has watched a blockbuster drug lose market exclusivity knows the same thing in hindsight: the scramble

The 180-day generic drug exclusivity period is, by raw financial math, one of the most lucrative regulatory prizes in the

Mark Cuban launched Cost Plus Drugs in January 2022 with a simple premise: buy generic drugs at manufacturer cost, add